Bio-discovery, PerkinElmer Life and Analytical Sciences, 940 Winter St., Waltham, MA, USA +1 781 663 5599 ; +1 781 663 5984 ;
Expert Opin Drug Discov. 2010 Mar;5(3):277-90. doi: 10.1517/17460441003636820. Epub 2010 Feb 18.
Protein kinases are important targets for drug discovery because they possess critical roles in many human diseases. Several protein kinase inhibitors have entered clinical development with others having already been approved for treating a host of diseases. However, many kinase inhibitors suffer from non-selectivity because they interact with the ATP binding region which has similar structures amongst the protein kinases and this non-selectivity sometimes can cause side effects. As a consequence, there is much interest in developing drugs that inhibit kinases through non-classical mechanisms with the hope of avoiding the side effects of previous kinase drugs.
This review covers emerging information on kinase biology and discusses new approaches to design selective inhibitors that do not compete with ATP.
The reader will gain a better understanding of the importance of the field of allosteric inhibitor drug discovery and how this has required the adoption of a new generation of high-throughput screening techniques.
Discovery and development of allosteric modulators will result in a family of novel kinase therapies with greater selectivity and more varied ways to control activity of disease causing kinase targets.
蛋白激酶是药物发现的重要靶点,因为它们在许多人类疾病中具有关键作用。一些蛋白激酶抑制剂已经进入临床开发阶段,其他一些已经被批准用于治疗多种疾病。然而,许多激酶抑制剂由于与 ATP 结合区域相互作用而具有非选择性,该区域在蛋白激酶之间具有相似的结构,这种非选择性有时会导致副作用。因此,人们非常有兴趣开发通过非经典机制抑制激酶的药物,希望避免以前激酶药物的副作用。
这篇综述涵盖了激酶生物学方面的新信息,并讨论了设计不与 ATP 竞争的选择性抑制剂的新方法。
读者将更好地了解变构抑制剂药物发现领域的重要性,以及这如何需要采用新一代高通量筛选技术。
变构调节剂的发现和开发将产生一系列新型激酶治疗药物,具有更高的选择性和更多控制疾病相关激酶靶标活性的方法。